Consistent with these findings, our study demonstrated that HSF1 knockdown suppressed DLBCL cell proliferation by modulating cell cycle progression and significantly enhanced their sensitivity to vincristine and doxorubicin both in vitro and in vivo. The gene discussed is HSF1; the disease is diffuse large B-cell lymphoma.